Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

NCT03284424 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC